CANCER THERAPY MARKET ANALYSIS

Cancer Therapy Market, By Therapy Type (Chemotherapy, Target Therapy, Immunotherapy, Radiotherapy, and Others), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Liver Cancer, Thyroid Cancer, Head and Neck Cancer, Skin Cancer, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI5335
Pages :174
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Cancer Therapy Market Regional Insights

To learn more about this report, Request sample copy

North America remains the dominant region in the global cancer therapy market and is anticipated to hold 41.9% of the market share in 2024. Increasing product approvals by regulatory authorities are expected to drive the North America cancer therapy market growth over the forecast period. For instance, on February 9, 2023, GSK plc., a biopharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer.

Overall, the Asia Pacific region offers pharmaceutical companies attractive opportunities due to its demographic and economic trends. With a more favorable regulatory environment emerging and urbanization amplifying healthcare demands, the market potential continues expanding at a rapid pace. If current momentum sustains, Asia Pacific may rival and even surpass North America as the top market for cancer therapies in the long run.